Stocktoria
Celldex Therapeutics, Inc. CLDX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1986-05-15
Celldex Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M |
| R&D expense | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M |
| Income tax | $0 | $0 | $0 | — | -$227,000 |
| Net income | -$258.8M | -$157.9M | -$141.4M | — | — |
| EPS (diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M | -$62.2M |
| Cash & equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M |
| Shareholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M |
Source: SEC EDGAR filings · CIK 0000744218 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.